Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-Siglec-2/CD22 Antibody (1R308) is a Rabbit antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (1R308) can be used in ELISA,IHC-P.
Description | Anti-Siglec-2/CD22 Antibody (1R308) is a Rabbit antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (1R308) can be used in ELISA,IHC-P. |
Ig Type | Monoclonal Rabbit IgG |
Clone | 1R308 |
Reactivity | Human |
Verified Activity | 1. Immunochemical staining of human CD22 in human spleen with rabbit monoclonal antibody at 1:200 dilution, formalin-fixed paraffin embedded sections. 2. Immunochemical staining of human CD22 in human tonsil with rabbit monoclonal antibody at 1:200 dilution, formalin-fixed paraffin embedded sections. |
Application | ELISA,IHC-P |
Recommended Dose | ELISA: 1:5000-1:10000; IHC-P: 1:100-1:500 |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human CD22 (rh CD22; TMPY-02034; P20273-1; Met1-Arg687). |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | CD22 is a member of the immunoglobulin superfamily, SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors, the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR, and this in turn is governed by the binding of its extracellular domain to alpha2,6-linked sialic acid ligands. However, genetic studies in mice reveal that some CD22 functions are regulated by ligand binding, whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Immunogen | Recombinant Human CD22 protein (TMPY-02034) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets, ITIM/ITAM Immunoreceptors and Related Molecules |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.